WINNIPEG, MANITOBA--(MARKET WIRE)--Jun 13, 2006 -- Miraculins Inc. (TSX VENTURE:MOM.V - News), a biotechnology company, dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce a collaboration agreement with Fox Chase Cancer Center in Philadelphia, to further the development of the Miraculins’ colorectal cancer diagnostic project.
